Study of pomalidomide and low dose dexamethasone with or without pembrolizumab (MK-3475) in refractory or relapsed and refractory multiple myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
The purpose of this study is to compare the efficacy of pomalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of pomalidomide and low dose dexamethasone without pembrolizumab in terms of Progression-Free Survival (PFS) in participants with refractory or relapsed and refractory multiple myeloma (rrMM) who have undergone at least 2 lines of prior treatment.
Study Type: InterventionalAllocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183)
Arms:
- Experimental: pembrolizumab+pomalidomide+dexamethasone
- Active Comparator: pomalidomide+dexamethasone
| Category | Value |
|---|---|
| Date last updated at source | 2017-06-16 |
| Study type(s) | Randomised clinical trial |
| Expected enrolment | 300 |
| Study start date | 2015-10-19 |
| Estimated primary completion date | 2019-10-31 |